Study of VX-985 in Subjects With Chronic Hepatitis C
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 64 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects who are male or females of non-childbearing potential aged 18 to 64 years(inclusive) with a body mass index (BMI) between 18 and 32 (kg/m2)
Certain subjects must agree to use acceptable contraceptive methods as specified in protocol
Subjects who are treatment naïve and are infected with genotype 1 chronic hepatitis C
Subjects must be in good health and have normal laboratory values as judged by investigator
Subjects must not have clinically significant abnormal results for physical examination
Subjects must not have received approved or experimental HCV therapy
Subjects must not have evidence of hepatic decompensation: history of ascites, hepatic encephalopathy, or bleeding esophageal varices
Subjects must not have any known history of other cause of significant liver disease including hepatitis B, drug or alcohol-related cirrhosis, etc
Subjects must not be diagnosed with or have suspected hepatocellular carcinoma
Subjects must not have histologic evidence of hepatic cirrhosis on any liver biopsy or test capable of detecting cirrhosis within the past 2 years
Subjects with a known history or other evidence of severe retinopathy or clinically significant ophthalmological disorder
Subjects must not have a history of any illness that might confound the results of the study or pose an additional risk in administering study drug(s) to the subject e.g. history of cardiovascular or central nervous system disease, ongoing psychiatric disorder, poorly controlled diabetes, etc
Subject must not have taken any of the prohibited medications within the specified time before study start or take certain medications (including herbal supplements) during the study
Subjects must not have a history of drug or alcohol abuse or addiction within 6 months before the start of dosing, or test positive for alcohol or drugs of abuse
Subjects must not have donated or had a significant loss of blood within 56 days of the start of dosing, or donated more than 1 unit of plasma within 7 days before the start of dosing
Subjects must not consume excessive amounts of caffeine
Subjects must not have participated in a clinical study involving administration of either an investigational or a marketed drug within 2 months
Subjects who are female and have a positive pregnancy test and/or who are considered to be of childbearing potential or are nursing.
Subjects that have a female partner who is pregnant, nursing, or planning to become pregnant during the study or shortly after the study